Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Cryptocurrency Fear and Greed Index Rises to 16, Market 'Fear' Emotion Slightly Eases

Cryptocurrency Fear and Greed Index Rises to 16, Market 'Fear' Emotion Slightly Eases

BlockBeatsBlockBeats2026/04/12 01:12

BlockBeats News, April 12th, according to Alternative data, today's cryptocurrency fear and greed index is 16 (yesterday was 15), and the market's "fear" sentiment has eased slightly.


Note: The fear index threshold is 0-100, including indicators: Volatility (25%) + Market Trading Volume (25%) + Social Media Hype (15%) + Market Sentiment (15%) + Bitcoin Dominance (10%) + Google Trends (10%).

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

UBS is bullish on CoreWeave (CRWV.US): Initiates "Buy" rating, betting on the return of AI trading rotation.

UBS has initiated coverage of the emerging cloud service provider CoreWeave (CRWV.US) with a "Buy" rating and set a target price of $120.

智通财经2026/09/24 07:01

Sixth increase in six years! Disney(DIS.US) raises the monthly fee for Disney+ ad-free version by 13% to $21.49.

Walt Disney Company (DIS.US) is raising subscription prices for several of its streaming services in the U.S. market, marking the sixth price increase in six years, as the company aims to boost the profitability of its streaming business, which is crucial for Disney's future.

智通财经2026/09/24 06:51

Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth

On September 24, according to the CDE website, Johnson & Johnson’s (JNJ.US) talquetamab (Chinese brand name: Tuolike) is proposed to be included in priority review.

智通财经2026/09/24 06:51
Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth